Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Idaho Technology Gains Army Approval Of Platinum Path™ Extraction Kit For Biological Pathogen Detection Program
Idaho Technology, Inc. has received the support of the U.S. Army Test and Evaluation Command (ATEC) for use of the Platinum Path™ Extraction Kit (PPEK) with the Joint Biological Agent Identification and Diagnostic System (JBAIDS).
generic viagra online
Young People At High HIV Risk Say Peers Should Teach Prevention
African-American adolescents have some of the highest rates of HIV infection in the United States, and efforts to educate them about preventing the disease must include the help of their adolescent peers, new research suggests.
News of the day
More Gene Mutations Linked To Autism Risk
More pieces in the complex autism inheritance puzzle are emerging in the latest study from a research team including geneticists from The Children"s Hospital of Philadelphia, the University of Pennsylvania School of Medicine and several collaborating institutions. This study identified 27 different genetic regions where rare copy number variations missing or extra copies of DNA segments were found in the genes of children with autism spectrum disorders (ASDs), but not in the healthy controls. The complex combination of multiple genetic duplications and deletions is thought to interfere with gene function, which can disrupt the production of proteins necessary for normal neurological development.
Medical Devices

Teva And Antares Announce FDA Approval Of Needle-Free Injector Product For Administration Of Tev-Tropin(R) (Human Growth Hormone)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (NYSE Amex: AIS) announced the approval of a Supplemental New Drug Application (sNDA), which added "needle-free injection" to its Tev-Tropin® [somatropin (rDNA) for injection] brand human growth hormone (hGH) drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system. "We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares, and to offer patients a less invasive delivery system," stated Larry Downey, head of Teva"s North America Brand Pharmaceuticals division. "This significant achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to utilize our global strengths in innovative activities." "This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the Company" said Paul K. Wotton, President and Chief Executive Officer of Antares Pharma. "Importantly it is another example of delivering on our strong focus and commitment to patients, together with our partners, to provide new ways to administer drugs. We look forward to the launch of this product by Teva." Human growth hormone is a protein given by injection that is commonly used to treat children with growth hormone deficiency. Pediatric patients benefit both from the avoidance of using needles as well as the rapid injection speed associated with giving needle-free injections. According to industry estimates, the market for human growth hormone in the United States is approximately $1 billion which is the largest market segment globally. Antares currently markets its needle-free injection system for use in the treatment of growth hormone deficient children through its partners in Europe, Japan and Asia. Tev-Tropin®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009